PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV · News & media

Mounjaro Approved For Weight Loss But Doctors Warn Against Side Effects

News & media8:31Nov 2023

Today’s cheapest tirzepatide$69/mo at Wellmedr, sale price.Compare all tirzepatide prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.

Our summary

This Health Boost segment covers the US FDA approval of Mounjaro for obesity. The hosts say the drug was already approved for people with diabetes and that the news is its approval for weight loss. They link its popularity to anecdotal evidence, some research and celebrity users, naming Elon Musk, Charles Barkley and Chelsea Handler. They stress it is for the clinically obese, needs a prescription, and is not meant for someone wanting a crash diet with no physical activity.

Published by India Today on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

A reporter's package says the weight loss brand name is Zepbound and that it competes with Novo's Wegovy. The report describes Mounjaro as acting on two receptors, GLP-1 and GIP. A doctor in the report says the appetite suppression and weight loss are remarkable, but that people with thyroid cancer or a family risk of it should not take it. Common side effects listed are vomiting, nausea, diarrhea, constipation and other gastrointestinal problems. The report says about 10% of people on the medicine dropped out of the most recent published trial because of such problems, against about 2% on dummy shots. It also says doctors warn that people who rely only on the drug regain weight once they stop.

Back in the studio, the hosts say the drug is popular in India, that some people source it from abroad, and that it is an expensive injection. They voice concern about overuse and misuse. One host says doctors report that brides wanting to lose 5 to 10 kg before a wedding are among the most frequent requesters, which the host calls dangerous. The segment closes with a note that research suggests it may be somewhat more effective than Ozempic, and with repeated advice to seek medical guidance.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 0:00 The hosts say Mounjaro, already approved for diabetes, has now been approved by the US FDA for obesity and requires a prescription.
  2. 1:00 They say it is meant for people who are clinically obese, not for crash dieting without physical activity.
  3. 1:30 They say the drug is popular in India, where some people buy it from outside the country, raising concern about misuse.
  4. 4:00 A doctor in the report says people with thyroid cancer or a family risk of it should not be given the drug.
  5. 4:30 The report lists common side effects and says about 10% of trial participants dropped out for such problems versus about 2% on dummy shots.
  6. 7:30 The hosts say brides wanting to lose 5 to 10 kg before a wedding are among those asking for it, and they call this dangerous.

Key moments

Tap one to play from there.

  1. 0:00 Introduction
  2. 3:19 How it works
  3. 4:24 Side effects

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
Mounjaro
Side effects mentioned
nausea and vomiting

Questions this video answers

Has Mounjaro been approved for weight loss?

According to the video, the US FDA has approved it for obesity after earlier approval for diabetes. The report gives the weight loss brand name as Zepbound. The hosts say it requires a prescription.

What are the side effects of Mounjaro?

The report lists vomiting, nausea, diarrhea, constipation and other gastrointestinal problems as common. It says about 10% of people in the most recent published trial dropped out because of such problems, compared with about 2% taking dummy shots.

Who should not take Mounjaro for weight loss?

A doctor in the video says people with thyroid cancer or a family risk of it should not be given it. The hosts also say it is for the clinically obese, not for people wanting a quick fix before an event.

Do you regain weight after stopping Mounjaro?

The report says doctors state that patients who rely only on the drug for weight loss regain the weight once they stop. The doctors quoted favor a holistic approach.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • Mounjaro for weight loss, and why Zepbound exists

    Mounjaro is tirzepatide approved for type 2 diabetes. Zepbound is the same molecule from the same maker, approved for weight management, and it goes to the same 15 mg. So unlike Ozempic and Wegovy, there is no dose ceiling pushing you from one to the other: the reason people move is coverage and cash price, not strength. Using Mounjaro for weight is off-label and a prescriber's decision. In the one head-to-head trial, tirzepatide beat semaglutide, 20.2% mean body-weight loss at 72 weeks against 13.7%.

  • Mounjaro side effects: the label's numbers by dose, the low blood sugar risk, and how tirzepatide compares at weight-loss doses

    On Mounjaro's own label, the common side effects are stomach ones and they rise with the dose: nausea in 12, 15 and 18 percent of people at 5, 10 and 15 mg against 4 percent on placebo, diarrhea 12 to 17 against 9, and any gastrointestinal reaction in 37 to 44 percent against 20. Most of it happens while the dose is being raised and fades. Low blood sugar is rare on Mounjaro alone and is mainly a risk when it is added to insulin or a sulfonylurea. Below: the full table, the rare warnings, and why Zepbound's numbers for the same molecule look higher.

  • How to get Mounjaro: the diabetes route, and why the weight route is a different box

    Mounjaro is approved for type 2 diabetes in adults and children from 10, and Lilly's own site says it is not a weight-loss drug. With a diabetes diagnosis, any prescriber can write it and a commercial plan that covers it brings it to $25 with Lilly's card. Without diabetes, a prescriber can write it off-label, but no insurer will cover it and LillyDirect self-pay starts at $499 a month, against a list price of $1,112.16 per fill. The same tirzepatide in the Zepbound box is approved for weight, plan-coverable, and sold direct for $299 to $699.

Next steps

Mounjaro prices

Insurance

Find more like it

Side effectsStopping and maintenanceHow it worksNauseaVomiting

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV